SE9600683D0 - Azabicyclic esters of carbamic acids useful in therapy - Google Patents

Azabicyclic esters of carbamic acids useful in therapy

Info

Publication number
SE9600683D0
SE9600683D0 SE9600683A SE9600683A SE9600683D0 SE 9600683 D0 SE9600683 D0 SE 9600683D0 SE 9600683 A SE9600683 A SE 9600683A SE 9600683 A SE9600683 A SE 9600683A SE 9600683 D0 SE9600683 D0 SE 9600683D0
Authority
SE
Sweden
Prior art keywords
alkyl
halogen
hydrogen
therapy
och3
Prior art date
Application number
SE9600683A
Other languages
English (en)
Swedish (sv)
Inventor
John Macor
Edwin Wu
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9600683A priority Critical patent/SE9600683D0/xx
Publication of SE9600683D0 publication Critical patent/SE9600683D0/xx
Priority to ZA9701082A priority patent/ZA971082B/xx
Priority to ARP970100618A priority patent/AR005876A1/es
Priority to IDP970487A priority patent/ID15969A/id
Priority to PL97328614A priority patent/PL328614A1/xx
Priority to AU22387/97A priority patent/AU706944B2/en
Priority to HK99102514.5A priority patent/HK1017357B/xx
Priority to SK1027-98A priority patent/SK102798A3/sk
Priority to DE69713295T priority patent/DE69713295T2/de
Priority to TR1998/01642T priority patent/TR199801642T2/xx
Priority to RU98117804A priority patent/RU2172739C2/ru
Priority to NZ331145A priority patent/NZ331145A/en
Priority to PCT/SE1997/000294 priority patent/WO1997030998A1/en
Priority to BR9707616A priority patent/BR9707616A/pt
Priority to EP97905544A priority patent/EP0885221B1/en
Priority to HU9901273A priority patent/HUP9901273A3/hu
Priority to US08/836,143 priority patent/US5998429A/en
Priority to CZ19982659A priority patent/CZ289110B6/cs
Priority to IL12562097A priority patent/IL125620A/en
Priority to CN97192461A priority patent/CN1063749C/zh
Priority to CA002246051A priority patent/CA2246051A1/en
Priority to AT97905544T priority patent/ATE219081T1/de
Priority to KR1019980706579A priority patent/KR19990087184A/ko
Priority to JP9530075A priority patent/JP2000505452A/ja
Priority to EE9800250A priority patent/EE9800250A/xx
Priority to NO983711A priority patent/NO983711L/no
Priority to IS4830A priority patent/IS4830A/is
Priority to US09/276,689 priority patent/US6054464A/en
Priority to IL13758500A priority patent/IL137585A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SE9600683A 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy SE9600683D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE9600683A SE9600683D0 (sv) 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy
ZA9701082A ZA971082B (en) 1996-02-23 1997-02-10 Azabicyclic esters of carbamic acids useful in therapy.
ARP970100618A AR005876A1 (es) 1996-02-23 1997-02-17 Esteres azabiciclicos de acidos carbamicos utiles en terapia, composicion farmaceutica que incluye a dichos esteres, uso de dichos esteres, metodos parael tratamiento o profilaxis de varios desordenes, enfermedades y adicciones, procedimiento para la preparacion de dichos esteres, intermediarios utilizados
IDP970487A ID15969A (id) 1996-02-23 1997-02-20 Ester azabisiklik asam karbamat yang berguna dalam terapi.
EE9800250A EE9800250A (et) 1996-02-23 1997-02-21 Teraapias kasutatavad karbaamhapete asabitsüklilised estrid
PCT/SE1997/000294 WO1997030998A1 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
CZ19982659A CZ289110B6 (cs) 1996-02-23 1997-02-21 Azabicyklické estery pro léčení poruch psychotických nebo naruąení intelektu
HK99102514.5A HK1017357B (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
SK1027-98A SK102798A3 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
DE69713295T DE69713295T2 (de) 1996-02-23 1997-02-21 Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
TR1998/01642T TR199801642T2 (xx) 1996-02-23 1997-02-21 Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
RU98117804A RU2172739C2 (ru) 1996-02-23 1997-02-21 Азабициклические сложные эфиры карбаминовых кислот, способы их получения, фармацевтическая композиция и промежуточные соединения
NZ331145A NZ331145A (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in treating disorders involving reduced cholinergic function
PL97328614A PL328614A1 (en) 1996-02-23 1997-02-21 Azabicyclic carbaminic esters useful in therapy
BR9707616A BR9707616A (pt) 1996-02-23 1997-02-21 Composto composiç o farmacéutica utilização de um composto e processo para a preparação de um composto para o tratamento ou profilaxia de distúrbios de deficiéncia intelectual ou profilaxia da doença de parkinson doença de huntington síndrome de tourette esclerose amiotrófica lateral ou distúrbios neurodegenerativos
EP97905544A EP0885221B1 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
HU9901273A HUP9901273A3 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
US08/836,143 US5998429A (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
AU22387/97A AU706944B2 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
IL12562097A IL125620A (en) 1996-02-23 1997-02-21 Azabicyclic esters of cereal phenylic and pyridylic acids, their preparations and medicinal preparations containing them
CN97192461A CN1063749C (zh) 1996-02-23 1997-02-21 用于治疗的氨基甲酸的氮杂双环酯
CA002246051A CA2246051A1 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
AT97905544T ATE219081T1 (de) 1996-02-23 1997-02-21 Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
KR1019980706579A KR19990087184A (ko) 1996-02-23 1997-02-21 치료에 유용한 카르밤산의 아자비시클릭 에스테르
JP9530075A JP2000505452A (ja) 1996-02-23 1997-02-21 治療に有用なカルバミン酸のアザビシクロエステル
NO983711A NO983711L (no) 1996-02-23 1998-08-13 Azabicykliske estere av karbaminsyrer som er nyttige i terapi
IS4830A IS4830A (is) 1996-02-23 1998-08-20 Asabísýklískir esterar af karbamiksýrum sem eru gagnlegir við læknismeðferð
US09/276,689 US6054464A (en) 1996-02-23 1999-03-26 Azabicyclic esters of carbamic acids useful in therapy
IL13758500A IL137585A0 (en) 1996-02-23 2000-07-30 Azabicyclic esters of phenyl and pyridyl carbamic adics, their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600683A SE9600683D0 (sv) 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy

Publications (1)

Publication Number Publication Date
SE9600683D0 true SE9600683D0 (sv) 1996-02-23

Family

ID=20401517

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600683A SE9600683D0 (sv) 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy

Country Status (26)

Country Link
US (2) US5998429A (cs)
EP (1) EP0885221B1 (cs)
JP (1) JP2000505452A (cs)
KR (1) KR19990087184A (cs)
CN (1) CN1063749C (cs)
AR (1) AR005876A1 (cs)
AT (1) ATE219081T1 (cs)
AU (1) AU706944B2 (cs)
BR (1) BR9707616A (cs)
CA (1) CA2246051A1 (cs)
CZ (1) CZ289110B6 (cs)
DE (1) DE69713295T2 (cs)
EE (1) EE9800250A (cs)
HU (1) HUP9901273A3 (cs)
ID (1) ID15969A (cs)
IL (2) IL125620A (cs)
IS (1) IS4830A (cs)
NO (1) NO983711L (cs)
NZ (1) NZ331145A (cs)
PL (1) PL328614A1 (cs)
RU (1) RU2172739C2 (cs)
SE (1) SE9600683D0 (cs)
SK (1) SK102798A3 (cs)
TR (1) TR199801642T2 (cs)
WO (1) WO1997030998A1 (cs)
ZA (1) ZA971082B (cs)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6277870B1 (en) * 1998-05-04 2001-08-21 Astra Ab Use
FR2804430B1 (fr) * 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6492386B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
WO2002016357A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
AU2001282875A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001284646A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282910A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
BR0212101A (pt) 2001-08-24 2004-08-24 Pharmacia & Up John Company 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
MXPA04000779A (es) * 2001-08-24 2004-04-20 Pharmacia & Up John Company 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades.
EP1425286B1 (en) * 2001-09-12 2007-02-28 Pharmacia & Upjohn Company LLC Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
ATE551340T1 (de) * 2001-10-02 2012-04-15 Pharmacia & Upjohn Co Llc Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
EP1442041A1 (en) 2001-11-08 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
MXPA04004373A (es) * 2001-11-09 2004-08-11 Upjohn Co Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
WO2003051302A2 (en) 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0307714A (pt) 2002-02-15 2005-02-09 Upjohn Co Benzoilamidas substituìdas com azabiciclo e tioamidas para tratamento de distúrbios relacionados ao cns
BR0307782A (pt) * 2002-02-19 2005-01-04 Upjohn Co Compostos azabiciclo para o tratamento de doença
MXPA04008038A (es) * 2002-02-19 2004-11-26 Upjohn Co Carboxamidas heteroaromaticas biciclicas condensadas con puente de n para el tratamiento de enfermedades.
US7001900B2 (en) * 2002-02-20 2006-02-21 Pfizer Inc. Azabicyclic compounds for the treatment of disease
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
AU2003253686A1 (en) 2002-08-01 2004-02-23 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
WO2004019943A1 (en) 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
HRP20050266A2 (en) 2002-09-25 2005-10-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and uses thereof
AU2003269401A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
WO2004052365A2 (en) 2002-12-06 2004-06-24 North Shore-Long Island Jewish Research Institute Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
CA2519265A1 (en) * 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
DE10334724A1 (de) * 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
ATE451368T1 (de) 2003-10-15 2009-12-15 Targacept Inc Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
AU2004309367B2 (en) 2003-12-22 2010-04-01 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US20050137217A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
FR2865208B1 (fr) * 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
EP2336128A1 (en) 2004-03-25 2011-06-22 Memory Pharmaceuticals Corporation Benzoisothiazoles and preparation and uses thereof
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
ATE487716T1 (de) 2004-04-22 2010-11-15 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen
JP2007538011A (ja) 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
ES2342675T3 (es) 2004-12-22 2010-07-12 Memory Pharmaceuticals Corporation Ligandos del receptor alfa-7 nicotinico contra enfermedades relacionadas con el snc.
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
AU2005323463B2 (en) 2004-12-27 2009-11-19 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
KR20080035649A (ko) 2005-08-22 2008-04-23 타가셉트 인코포레이티드 헤테로아릴로 치환된 디아자트리시클로알칸, 그 제조방법및 용도
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
RU2441868C2 (ru) * 2007-02-09 2012-02-10 Астеллас Фарма Инк. Аза-кольцевое соединение с внутренним мостиком
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
EP2217597B1 (en) 2007-10-01 2011-03-30 Comentis, Inc. Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
JP2011511845A (ja) 2008-02-13 2011-04-14 ターガセプト，インコーポレイテッド アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
KR20110019781A (ko) 2008-06-20 2011-02-28 아스트라제네카 아베 디벤조티아제핀 유도체 및 그의 용도
AU2009316801C1 (en) 2008-11-18 2015-12-24 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflammatory stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
UY32397A (es) * 2009-01-28 2010-08-31 Astrazeneca Ab Compuestos de 2-aza-biciclo [2,2,1] heptano y sus usos
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
FR2948368B1 (fr) * 2009-07-21 2011-07-22 Servier Lab Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
AU2010336337B2 (en) 2009-12-23 2016-02-04 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
CA2989633A1 (en) 2010-05-17 2011-11-24 Forum Pharmaceuticals Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
HUE064200T2 (hu) * 2013-03-15 2024-02-28 Genzyme Corp Eljárás glukozilceramid szintáz inhibitorok elõállítására
US10208016B2 (en) 2013-06-21 2019-02-19 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9434724B2 (en) 2014-07-11 2016-09-06 Alpharmagen, Llc Quinuclidines for modulating alpha 7 activity
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTIVE CHARGING SYSTEMS
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
DE102017210141A1 (de) 2017-06-16 2018-12-20 Henkel Ag & Co. Kgaa Portion zur Bereitstellung tensidhaltiger Flotten
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
CN114746422B (zh) * 2019-11-15 2024-03-12 柳韩洋行 具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐以及包含它们的药物组合物
MX2022005679A (es) * 2019-11-15 2022-06-27 Yuhan Corp Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden.
WO2021156769A1 (en) 2020-02-03 2021-08-12 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
WO2022018695A1 (en) 2020-07-24 2022-01-27 Genzyme Corporation Pharmaceutical compositions comprising venglustat
CN117222645A (zh) * 2021-05-11 2023-12-12 柳韩洋行 对葡萄糖神经酰胺合成酶具有抑制活性的新颖的化合物或其药学上可接受的盐、其制备方法以及包含其的药物组合物
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
AU2023368362A1 (en) * 2022-10-24 2025-03-20 Green Cross Corporation Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives
IL319916A (en) * 2022-10-24 2025-05-01 Yuhan Corp A new salt of a derivative of dimethyl-3,2-dihydro-1H-indene and processes for its preparation
WO2025159544A1 (en) * 2024-01-26 2025-07-31 Yuhan Corporation Pharmaceutical composition for preventing or treating gaucher disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU482990A1 (ru) * 1973-09-03 1978-04-15 Предприятие П/Я Г-4059 Способ получени 1,4-диазабицикло(2,2,2)-октана
DE8817121U1 (de) * 1988-11-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Quinuclidine
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
US5530018A (en) * 1994-02-04 1996-06-25 G. D. Searle & Co. Meso-azanoradamantanes
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives

Also Published As

Publication number Publication date
CZ265998A3 (cs) 2000-02-16
IL137585A0 (en) 2001-07-24
ID15969A (id) 1997-08-21
US6054464A (en) 2000-04-25
EP0885221B1 (en) 2002-06-12
RU2172739C2 (ru) 2001-08-27
AU706944B2 (en) 1999-07-01
KR19990087184A (ko) 1999-12-15
BR9707616A (pt) 1999-07-27
NZ331145A (en) 2000-02-28
SK102798A3 (en) 1999-01-11
CN1063749C (zh) 2001-03-28
DE69713295D1 (de) 2002-07-18
EE9800250A (et) 1999-02-15
NO983711D0 (no) 1998-08-13
IL125620A (en) 2001-09-13
WO1997030998A1 (en) 1997-08-28
US5998429A (en) 1999-12-07
CN1211983A (zh) 1999-03-24
ZA971082B (en) 1997-08-25
AR005876A1 (es) 1999-07-21
DE69713295T2 (de) 2003-01-09
AU2238797A (en) 1997-09-10
JP2000505452A (ja) 2000-05-09
NO983711L (no) 1998-08-13
IL125620A0 (en) 1999-04-11
HUP9901273A3 (en) 2000-06-28
CA2246051A1 (en) 1997-08-28
CZ289110B6 (cs) 2001-11-14
ATE219081T1 (de) 2002-06-15
TR199801642T2 (xx) 1998-11-23
IS4830A (is) 1998-08-20
HK1017357A1 (en) 1999-11-19
EP0885221A1 (en) 1998-12-23
HUP9901273A2 (hu) 1999-07-28
PL328614A1 (en) 1999-02-01

Similar Documents

Publication Publication Date Title
SE9600683D0 (sv) Azabicyclic esters of carbamic acids useful in therapy
ATE63742T1 (de) Chinazolinon-derivate.
ATE399753T1 (de) Amide als pyruvatdehydrogenaseinhibitoren
MY118109A (en) Novel aralkyl amines of spirofuropyridines useful in therapy
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
SE9701144D0 (sv) Novel compounds, their use and preparation
SE0104334D0 (sv) Therapeutic agents
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
MY119542A (en) Therapeutic biaryl derivatives
ATE524443T1 (de) Bicyclische inhibitoren von mek und verfahren zu deren herstellung
HUP0001760A2 (hu) Aril-acil-piridazin-származékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és a vegyületek alkalmazása gyógyszerkészítmények előállítására
ES8607298A1 (es) Procedimiento para la preparacion de pirazolopiridinas.
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
NZ528997A (en) Sulfonamides
NO852026L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive bis -(4-aminofenyl)-sulfoner.
ES8606337A1 (es) Un procedimiento para preparar nuevas benzamidas con actividada antagonista de 5-ht.
NO160783C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive substituerte beta-karbolinderivater.
ES2000524A6 (es) Procedimiento para la preparacion de nuevas benzamidas y benzoatos sustituidos.
SE0104333D0 (sv) Therapeutic agents
PT1430047E (pt) Derivados de alquilaminopiridazinona substituida, processo para a sua preparacao e composicoes farmaceuticas que os contem
EA200500738A1 (ru) КРИСТАЛЛИЧЕСКИЕ ФУМАРАТНЫЕ СОЛИ 1-АЗАБИЦИКЛО [2.2.2]ОКТЗАМЕЩЕННОГО ФУРО [2,3-c] ПИРИДИНИЛКАРБОКСАМИДА И ИХ КОМПОЗИЦИИ И ПОЛУЧЕНИЕ
ES8801212A1 (es) Un procedimiento para preparar 5,8,13,14-tetrahido-(9- y 12 -hidroxi)-14-metilben (5,6)-isoindolo (2,1-b)isoquinolin-8,13-diona
SE0400440D0 (sv) Novel Cinnamic Amides
ATE41770T1 (de) Derivate von n-(2-pyrrolidinylmethyl)benzamid, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zubereitung.
MX9601953A (es) Nuevo compesto derivados de 5h-tiazolo [3,2-a] pirimidin-5-ona.